Intellia Therapeutics (NTLA)
Develops CRISPR medicines led by lonvo-z and nex-z.
$12.18
vs last close−0.51 (−4.00%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 103.31% | 144.76M shares | |
|---|---|---|---|
| 354 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.83% | 2.56M shares | |
| 16 holders · as of Aug 24, 2026 | |||
| Adds to | 105.14% | ||
140.13M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 105.14%; nothing is left for Other.
13F, as of Jun 30, 2026
354 holders · 144.76M shares · 56 new positions · 196 increased · 83 reduced · 30 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ark Investment Management LLC | 16.88M | 12.04% | +2.37M | Aug 14, 2026 |
| BlackRock, Inc. | 15.41M | 11.00% | +3.25M | Aug 7, 2026 |
| State Street Corp | 9.23M | 6.59% | +2.31M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 7.33M | 5.23% | +1.11M | Aug 13, 2026 |
| D. E. Shaw & Co., Inc. | 6.44M | 4.60% | +715.1K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 6.03M | 4.30% | +944.5K | Aug 13, 2026 |
| Two Sigma Investments, LP | 5.24M | 3.74% | +529.4K | Aug 14, 2026 |
| FMR LLC | 4.77M | 3.41% | +2.71M | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 12.27% | 14.21M | 13G | Feb 3, 2026 |
| BlackRock, Inc. | 8.20% | 8.45M | 13G | Apr 17, 2025 |
| State Street Corporation | 6.80% | 9.23M | 13G | Aug 7, 2026 |
| Vanguard Portfolio Management | 5.30% | 6.27M | 13G | Apr 29, 2026 |
| Vanguard Capital Management | 5.03% | 5.95M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 21, 2026 | John M. Leonarddirector, officer: President and CEO | Sale | 2,785 | $13.00 | 1,147,064 |
| Aug 20, 2026 | John M. Leonarddirector, officer: President and CEO | Sale | 19,890 | $12.60 | 1,149,849 |
| Jul 22, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 8,111 | $11.25 | 148,175 |
| Jul 2, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 4,677 | $18.00 | 156,286 |
| Jul 1, 2026 | Michael P. Dubeofficer: VP, Chief Accounting Officer | Sale | 2,641 | $16.78 | 66,886 |
| Mar 2, 2026 | Eliana Clarkofficer: EVP, Chief Technical Officer | Sale | 607 | $13.78 | 93,864 |
| Mar 2, 2026 | James Bastaofficer: EVP, General Counsel | Sale | 1,211 | $13.78 | 156,794 |
| Jan 5, 2026 | Michael P. Dubeofficer: VP, Chief Accounting Officer | Sale | 2,989 | $9.21 | 52,277 |
| Jan 5, 2026 | Edward J. III Dulacofficer: EVP, Chief Financial Officer | Sale | 6,379 | $9.21 | 99,683 |
| Jan 5, 2026 | Eliana Clarkofficer: EVP, Chief Technical Officer | Sale | 9,515 | $9.21 | 87,118 |
House and Senate disclosures
Not reported.